glesatinib

Glesatinib is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. It primarily targets the mesenchymal epithelial transition factor (MET) and AXL receptor tyrosine kinases, as well as other kinases such as Tek/Tie2 and vascular endothelial growth factor receptors (VEGFR1/2/3). By inhibiting these kinases, glesatinib disrupts signaling pathways involved in tumor cell proliferation and angiogenesis. It has been investigated mainly for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with MET dysregulation (mutations or amplification), both as monotherapy and in combination regimens. Glesatinib has shown modest clinical activity in phase 2 trials for NSCLC patients with MET alterations[2][3][4][5][7].

Other names

glesatinib